BioMarcK Pharmaceuticals is Drug Discovery in United States that focus on obstructive pulmonary disease business. Founded in 2002. They cover business area such as operator, novel drug, acute respiratory distress syndrome, chronic obstructive pulmonary disease, cancer, anti-marcks protein, respiratory disease, physician, safe and targeted treatment, patient, airway inflammation.
2002
( 22 years old in 2024 )
Obstructive Pulmonary Disease
-
41 University Drive
Suite 400
Newtown, PA 18940
United States
Private
operatornovel drugacute respiratory distress syndromechronic obstructive pulmonary diseasecanceranti-marcks proteinrespiratory diseasephysiciansafe and targeted treatmentpatientairway inflammation
* We use standard office opening hours in near BioMarcK Pharmaceuticals's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
BioMarcK Pharmaceuticals is Drug Discovery business from United States that founded in 2002 (22 years old in 2024), BioMarcK Pharmaceuticals business is focusing on Obstructive Pulmonary Disease.
BioMarcK Pharmaceuticals headquarter office and corporate office address is located in 41 University Drive Suite 400 Newtown, PA 18940 United States.
BioMarcK Pharmaceuticals was founded in United States.
In 2024, BioMarcK Pharmaceuticals is currently focus on obstructive pulmonary disease sector.
Above is snippet of Google Trends for "obstructive pulmonary disease" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with BioMarcK Pharmaceuticals, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
